Objectives: To identify areas of agreement and disagreement in the implementation of multi-parametric magnetic resonance imaging (mpMRI) of the prostate in the diagnostic pathway.
Materials And Methods: Fifteen UK experts in prostate mpMRI and/or prostate cancer management across the UK (involving nine NHS centres to provide for geographical spread) participated in a consensus meeting following the Research and Development Corporation and University of California-Los Angeles (UCLA-RAND) Appropriateness Method, and were moderated by an independent chair. The experts considered 354 items pertaining to who can request an mpMRI, prostate mpMRI protocol, reporting guidelines, training, quality assurance (QA) and patient management based on mpMRI levels of suspicion for cancer. Each item was rated for agreement on a 9-point scale. A panel median score of ≥7 constituted 'agreement' for an item; for an item to reach 'consensus', a panel majority scoring was required.
Results: Consensus was reached on 59% of items (208/354); these were used to provide recommendations for the implementation of prostate mpMRI in the UK. Key findings include prostate mpMRI requests should be made in consultation with the urological team; mpMRI scanners should undergo QA checks to guarantee consistently high diagnostic quality scans; scans should only be reported by trained and experienced radiologists to ensure that men with unsuspicious prostate mpMRI might consider avoiding an immediate biopsy.
Conclusions: Our consensus statements demonstrate a set of criteria that are required for the practical dissemination of consistently high-quality prostate mpMRI as a diagnostic test before biopsy in men at risk.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334741 | PMC |
http://dx.doi.org/10.1111/bju.14361 | DOI Listing |
BMC Cancer
January 2025
Department of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, 350001, Fujian Province, China.
Background: Prostate cancer (PCa) is definitively diagnosed by systematic prostate biopsy (SBx) with 13 cores. This method, however, can increase the risk of urinary retention, infection and bleeding due to the excessive number of biopsy cores.
Methods: We retrospectively analyzed 622 patients who underwent SBx with prostate multiparametric MRI (mpMRI) from two centers between January 2014 to June 2022.
Quant Imaging Med Surg
January 2025
Department of Nuclear Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background: Although F-prostate-specific membrane antigen-1007 (F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance imaging (mpMRI) are good predictors of prostate cancer (PCa) prognosis, their combined ability to predict prostate-specific antigen (PSA) persistence has not been thoroughly evaluated. In this study, we assessed whether clinical, mpMRI, and F-PSMA-1007 PET/CT characteristics could predict PSA persistence in patients with PCa treated with radical prostatectomy (RP).
Methods: This retrospective study involved consecutive patients diagnosed with PCa who underwent both preoperative mpMRI and PSMA PET/CT scans between April 2019 and June 2022.
Radiol Imaging Cancer
January 2025
From the Department of Radiology (A.C., A.N.Y., R.E., C.H., G.L., M.M., E.B.J., A.L.C., B.G., G.S.K., A.O.), Sanford J. Grossman Center of Excellence in Prostate Imaging and Image Guided Therapy (A.C., A.N.Y., M.M., A.L.C., B.G.), Department of Surgery, Section of Urology (G.G., L.F.R., P.K.M., S.E.), Department of Pathology (T.A.), and Department of Public Health Sciences (M.G.), University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637.
Purpose To evaluate the use of an automated hybrid multidimensional MRI (HM-MRI)-based tool to prospectively identify prostate cancer targets before MRI/US fusion biopsy in comparison with Prostate Imaging and Reporting Data System (PI-RADS)-based multiparametric MRI (mpMRI) evaluation by expert radiologists. Materials and Methods In this prospective clinical trial (ClinicalTrials.gov registration no.
View Article and Find Full Text PDFUrology
January 2025
S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Objectives: To evaluate the impact of Aquablation on circulating tumor cells (CTCs) in men with localized prostate cancer.
Methods: This prospective study included subjects with biopsy-positive mpMRI visible lesions (PIRADS ≥ 3) who underwent Aquablation. Ten ml blood samples were collected before, during and after the procedure to measure CTC counts using an immunofluorescence assay.
Prostate Int
September 2024
Gazi University School of Medicine, Urology Department, Ankara, Turkey.
Aim: To investigate the predictive value of lesion length in multiparametric prostate magnetic resonance imaging with respect to prostate volume for clinically significant prostate cancer diagnosis in targeted biopsies.
Materials And Methods: The data of biopsy-naïve patients in the Turkish Urooncology Association Prostate Cancer Database who underwent targeted prostate biopsies were included in this study. Lesion density is calculated as the ratio of lesion length (mm) in MR to prostate volume (cc).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!